These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9151153)

  • 1. The use of a heparin removal device: a valid alternative to protamine.
    Hendrikx M; Leunens V; Vandezande E; Wallyn A; Flameng W
    Int J Artif Organs; 1997 Mar; 20(3):166-74. PubMed ID: 9151153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of anticoagulation without protamine using a heparin removal device after cardiopulmonary bypass.
    Vertress RA; Zwischenberger JB; McRea JC; Tao W; Kurusz M; Conti VR
    ASAIO J; 1994; 40(3):M560-4. PubMed ID: 8555577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin removal after cardiopulmonary bypass in a patient with adverse reaction to protamine.
    Tevaearai HT; Jegger D; Mueller XM; Horisberger J; von Segesser LK
    Thorac Cardiovasc Surg; 1998 Oct; 46(5):303-4. PubMed ID: 9885123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a heparin removal device in comparison with protamine after hypothermic cardiopulmonary bypass.
    Tao W; Deyo DJ; Brunston RL; Vertrees RA; Grochoske TL; Zwischenberger JB
    ASAIO J; 1997; 43(5):M825-30. PubMed ID: 9360162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flow rate dependent ex vivo deheparinization with immobilized cationic ligand.
    Tevaearai HT; Mueller XM; Marty B; Horisberger J; Schapira M; von Segesser LK
    ASAIO J; 1997; 43(5):M487-9. PubMed ID: 9360090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery.
    Vonk AB; Veerhoek D; van den Brom CE; van Barneveld LJ; Boer C
    J Cardiothorac Vasc Anesth; 2014 Apr; 28(2):235-41. PubMed ID: 24342152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracorporeal heparin adsorption following cardiopulmonary bypass with a heparin removal device--an alternative to protamine.
    Tao W; Deyo DJ; Brunston RL; Vertrees RA; Zwischenberger JB
    Crit Care Med; 1998 Jun; 26(6):1096-102. PubMed ID: 9635661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin clearance profiles after systemic anticoagulation using a heparin removal device system.
    Tao W; Callahan JD; Vertrees RA; Brunston RL; Deyo DJ; McRea JC; Zwischenberger JB
    ASAIO J; 1997; 43(6):922-6. PubMed ID: 9386844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of protamine hollow-fiber device for extracorporeal heparin removal.
    Liang JF; Emregul E; Yang VC
    Blood Purif; 2004; 22(2):198-202. PubMed ID: 15044818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged Activated Clotting Time after Protamine Administration Does Not Indicate Residual Heparinization after Cardiopulmonary Bypass in Pediatric Open Heart Surgery.
    Yamamoto T; Wolf HG; Sinzobahamvya N; Asfour B; Hraska V; Schindler E
    Thorac Cardiovasc Surg; 2015 Aug; 63(5):397-403. PubMed ID: 26121380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are the point-of-care diagnostics MULTIPLATE and ROTEM valid in the setting of high concentrations of heparin and its reversal with protamine?
    Gertler R; Wiesner G; Tassani-Prell P; Braun SL; Martin K
    J Cardiothorac Vasc Anesth; 2011 Dec; 25(6):981-6. PubMed ID: 21315618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A protamine filter for extracorporeal blood heparin removal.
    Teng CL; Kim JS; Port FK; Wakefield TW; Till GO; Yang VC
    ASAIO Trans; 1988; 34(3):743-6. PubMed ID: 3196594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A protamine filter for extracorporeal heparin removal. Development, testing, blood compatibility evaluation, and future direction.
    Byun Y; Yun JH; Han IS; Fu Y; Shanberge JN; Yang VC
    ASAIO J; 1995; 41(3):M301-5. PubMed ID: 8573812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of differing rates of protamine reversal of heparin anticoagulation.
    Wakefield TW; Hantler CB; Wrobleski SK; Crider BA; Stanley JC
    Surgery; 1996 Feb; 119(2):123-8. PubMed ID: 8571194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring and management of anticoagulation in children requiring extracorporeal circulation.
    Malviya S
    Semin Thromb Hemost; 1997; 23(6):563-7. PubMed ID: 9469631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuation of hemodynamic and hematologic effects of heparin-protamine sulfate interaction after aortic reconstruction in a canine model.
    Wakefield TW; Lindblad B; Whitehouse WM; Hantler CB; Stanley JC
    Surgery; 1986 Jul; 100(1):45-51. PubMed ID: 3726760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly-L-lysine amplification of protamine immobilization and heparin adsorption.
    Zhang Y; Singh VK; Yang VC
    J Biomed Mater Res; 1998 Nov; 42(2):182-7. PubMed ID: 9773814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety issues in heparin and protamine administration for extracorporeal circulation.
    Jobes DR
    J Cardiothorac Vasc Anesth; 1998 Apr; 12(2 Suppl 1):17-20. PubMed ID: 9583571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass.
    Stafford-Smith M; Lefrak EA; Qazi AG; Welsby IJ; Barber L; Hoeft A; Dorenbaum A; Mathias J; Rochon JJ; Newman MF;
    Anesthesiology; 2005 Aug; 103(2):229-40. PubMed ID: 16052104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel approach to anticoagulation control.
    Kim JS; Vincent C; Teng CL; Wakefield TW; Yang VC
    ASAIO Trans; 1989; 35(3):644-6. PubMed ID: 2597555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.